SCHEDULE: Millennium Management Discloses Stake in Forte Biosciences

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 3.2% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, indicating their beneficial ownership of Forte Biosciences, Inc. common stock.
• The filing, dated June 30, 2026, states that these entities collectively beneficially own 655,199 shares of Forte Biosciences, Inc. common stock.
• This represents approximately 3.2% of the class of securities outstanding.
• The shares are held by entities subject to the voting control and investment discretion of Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
• The filing clarifies that this is not an admission of beneficial ownership by the named entities for all held securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports existing beneficial ownership without new strategic information or performance data.

Positives

• Significant institutional investor presence indicated by the filing.
• The filing confirms a substantial, though not controlling, stake in the company.

Negatives

• The filing does not provide details on the investment strategy or rationale behind acquiring the stake.

Risks

• Potential for future changes in beneficial ownership, which could impact share price.
• The concentration of voting power and investment discretion among a few entities could influence corporate actions.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance or strategy.

Management Comments

• "The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large investment management firms like Millennium Management often signal a significant interest in a company's stock, potentially influencing market perception and trading activity.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, but the passive nature of the filing suggests no immediate strategic shift.
• Management: Will be aware of the significant stake held by a major investment firm, potentially influencing future strategic decisions.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued monitoring of Forte Biosciences, Inc. by Millennium Management LLC and its affiliates.
• Potential for future amendments to the Schedule 13G if ownership levels change significantly.

Key Dates

Keywords

Forte Biosciences, Millennium Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management